HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis